Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853414 | 1.00 | MRGPRX4 (0.45) | MRGPRX4TAS2R14KDM4ELMNAMPO | |
| SCHEMBL29382578 | 0.92 | KDM4E (0.46) | MRGPRX4TAS2R14KDM4ELMNAMPO | |
| SCHEMBL22833395 | 0.92 | KDM4E (0.46) | MRGPRX4TAS2R14KDM4ELMNAMPO | |
| SCHEMBL29383454 | 0.89 | CFTR (0.50) | MRGPRX4TAS2R14MPOSCN8ASCN10A | |
| SCHEMBL22833864 | 0.89 | CFTR (0.50) | MRGPRX4TAS2R14MPOSCN8ASCN10A | |
| SCHEMBL22853040 | 0.87 | CDC25B (0.48) | MRGPRX4MPOTHRBSCN8ASCN10A | |
| SCHEMBL30294858 | 0.87 | CDC25B (0.48) | MRGPRX4MPOTHRBSCN8ASCN10A | |
| SCHEMBL22853053 | 0.86 | MRGPRX4 (0.42) | MRGPRX4TAS2R14KDM4ELMNAMPO | |
| SCHEMBL30294656 | 0.86 | MRGPRX4 (0.42) | MRGPRX4TAS2R14KDM4ELMNAMPO | |
| SCHEMBL22853409 | 0.85 | SMN1; SMN2 (0.50) | KDM4ELMNATHRBTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | MRGPRX4 510/4885TAS2R14 1406/4885KDM4E 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.